videos of cockfighting
North Korea vows toughest anti-US policy before Trump takes officeGamers should take advantage of this Samsung monitor discount
Janet Yellen tells Congress US could hit debt limit in mid-January(The Center Square) – The State Board of Education (SBOE) on Friday approved the Texas Education Agency’s (TEA) proposal for Texas’ state-owned textbooks, known as Bluebonnet Learning. It passed by a vote of 8-7. It includes new Mathematics curriculum for K-8 students, new Language Arts material for K-5 students and additional instructional support for teachers. Gov. Greg Abbott lauded the vote, saying, “The passage of Bluebonnet Learning is a critical step forward to bring students back to the basics of education and provide the best education in the nation.” He also notes that the materials are voluntary and free for use. Parents and the public are able to access the materials at tea.texas.gov/bluebonnet . The “transformative educational materials ... will ensure young Texans have access to high-quality, grade-level appropriate curricula that will provide the necessary fundamentals in math, reading, science, and other core subjects and boost student outcomes across Texas,” Abbott said. The new curriculum stems from HB 1605, filed in 2023 by state Rep. Brad Buckley, R-Killeen, which passed the legislature and Abbott signed into law. It requires the TEA to provide Open Education Resources (OER) textbooks for core subjects, including reading and math for Pre-K to 8th grade. It also directed the TEA to appoint an advisory board to ensure the materials are high quality and compliant with state standards. The materials were subject to approval by the SBOE. The curriculum is voluntary, but school districts will receive additional funding if they use them. If they opt-in to use Bluebonnet Learning, a second stream of additional funding will be made available to defray printing costs. Abbott said in May when the materials were made available for public review that they will “provide the necessary fundamentals in math, reading, science, and other core subjects” and “allow our students to better understand the connection of history, art, community, literature, and religion on pivotal events like the signing of the U.S. Constitution, the Civil Rights Movement, and the American Revolution,” The Center Square reported . Of the several issues opponents criticized, chief among them is proposed curriculum in the Language Arts material related to Christianity and the Bible. Sign up to get our free daily email of the biggest stories! The American Federation of Teachers-Texas Chapter also took issue with additional state funding only being made available to school districts that opt-in, arguing the process is unethical and violates educational standards. “Every educator in this state agrees to a Code of Ethics . Among the standards we are expected to uphold by the state of Texas is that we shall not exclude a student from participation in a program, deny benefits to a student, or grant an advantage to a student on the basis of race, color, gender, disability, national origin, religion, family status, or sexual orientation,” AFT-Texas Chapter President Zeph Capo said . “Texas has a way of forcing us to violate this standard, usually about the time that the Legislature ends its session and the governor puts his pen to the signature line of so many counterproductive, detrimental bills. Today, though, it is the State Board of Education that has put us in the position of defying our Code of Ethics once more. “On Nov. 22, in a close vote that crossed party lines and was separated only by a last-minute political appointee, the SBOE voted to approve Bluebonnet Learning materials as curriculum resources for Texas public school districts.” Capo also said the materials “are not just inappropriate – they’re bad at what they proclaim to do. Instructional experts have expressed deep concerns about the age-appropriateness of the materials and whether they will be effective reading instruction.” The vote was held after significant public input. On Monday, more than 150 people signed up to testify before the board about the curriculum. On Tuesday, board members took a preliminary vote, 8-7, indicating it had enough votes to adopt the curriculum. This is after thousands weighed in after the material was made public in May. “A highly transparent, three-month public feedback period began in May 2024, giving the public an opportunity to review and offer comments on the proposed materials. The SBOE also welcomed several hours of public testimony at its September meeting where additional feedback on the product was received. TEA used these comments and feedback to further refine, edit and ready the product for final submission as part of the SBOE’s Instructional Materials Review and Approval (IMRA) process - ensuring the materials are aligned with state standards and values,” the TEA explains. “The branding of Bluebonnet Learning began with feedback from teachers and parents seeking a clear, distinctive name to make the materials easier to recognize for educators and school systems. Bluebonnet Learning materials are Texas Open Education Resources (OER), meaning they are owned by the state, made available free to anyone, and can be modified over time to make them better for students and teachers.”
Beyond screen time: Complex factors shaping child development
The New York Jets are turning to one of their former general managers to help them find their next GM and head coach. The franchise announced Monday that The 33rd Team, a football media, analytics and consulting group founded by former Jets GM Mike Tannenbaum, will assist team owner Woody Johnson in the searches. Tannenbaum and Rick Spielman, former GM of the Miami Dolphins and Minnesota Vikings, will be The 33rd Team's primary representatives in helping find replacements for former coach Robert Saleh and GM Joe Douglas. The 33rd Team was founded in 2019 by Tannenbaum as a media and technology company. In their announcement, the Jets said The 33rd Team will help identify and vet GM and coach candidates and coordinate interviews. Douglas was fired last Tuesday , the latest shakeup for a franchise that had Super Bowl aspirations with a healthy Aaron Rodgers at quarterback but has limped to a 3-8 start and appears likely to miss the playoffs for a 14th consecutive year. Phil Savage, a senior football adviser with the Jets since 2019, will serve as the interim general manager for the rest of the season. The firing of Douglas came exactly six weeks after Johnson fired Saleh as coach on Oct. 8 after the Jets were 2-3 to open the season. New York has since gone 1-5 under defensive coordinator Jeff Ulbrich, who was tabbed as the interim coach. The Jets are coming off their bye-week break and will host the Seattle Seahawks on Sunday. The franchise has plenty of questions to answer over the next several months, including decisions on their next general manager and coach — and the future of Rodgers. The four-time NFL MVP turns 41 next week, has dealt with leg issues all season and is off to the worst statistical start of his career. Tannenbaum and Spielman will help the Jets find the people to help Johnson and brother Christopher make those key decisions. Johnson took a similar approach in 2015, the last time the Jets hired a general manager and coach in the offseason. Former NFL GMs Charley Casserly and Ron Wolf worked as consultants for the team, which hired Mike Maccagnan as GM and Todd Bowles as coach. Tannenbaum, currently an analyst for ESPN, has first-hand familiarity with Johnson and the franchise. He worked in the Jets' front office for nine years before being promoted to general manager and serving in that role from 2006 to 2012. Tannenbaum helped build the 2009 and 2010 Jets teams that went to the AFC championship game in consecutive seasons under coach Rex Ryan. Ryan, who last coached the Jets in 2014 and also is currently an analyst for ESPN, recently has been lobbying on air for a return to New York's sideline. Tannenbaum also was Miami’s executive vice president of football operations from 2015 to 2018. Spielman served as the Vikings’ general manager from 2012 to 2021 after working as the team’s vice president of player personnel for six years. He was also the Dolphins’ GM in 2004 and served as an adviser last year for the Washington Commanders in their GM and coaching searches. This story has been corrected to show that Spielman was formerly GM of the Minnesota Vikings instead of the Detroit Lions. AP NFL: https://apnews.com/hub/NFLNew York, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight The launch of upcoming therapies such as ITM-11, CAM2029, RYZ101, CABOMETYX, ALPHAMEDIX, and others in the forecast period, rising incident population due to an increased number of endoscopic and radio-imaging studies, increasing research activities are driving neuroendocrine tumor market size. Companies such as Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, and others are competing fiercely to capture the largest market sizes. DelveInsight's latest Neuroendocrine Tumors Market Insights report includes a comprehensive understanding of current treatment practices, emerging neuroendocrine tumor drugs, market share of individual therapies, and current and forecasted neuroendocrine tumors market size from 2020 to 2034, segmented into 6MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom]. Key Takeaways from the Neuroendocrine Tumors Market Report According to DelveInsight's analysis, the market size of neuroendocrine tumors in the US was USD 1.5 billion in 2023. In 2023, Somatostatin analogs (SSAs) captured the highest market size of approximately USD 700 million in the US, followed by LUTATHERA . However, by 2034, radioligand treatments including approved beta emitter-radioligand therapy [LUTATHERA], and most anticipated alpha emitter-based therapies are expected to drive the overall NETs market size. The total number of incident cases of NETs in the US was nearly 29,500 cases in 2023 and is projected to increase by 2034. Prominent emerging companies working in the domain of neuroendocrine tumors, including ITM Solucin GMBH , Camurus , Bristol Myers Squibb , Rayzebio , Exelixis , Ipsen , Takeda , Radiomedix , Orano Med , Perspective Therapeutics , Elicera Therapeutics , Chimerix , Enterome , Teclison , and others, are actively working on innovative neuroendocrine tumor drugs. These novel neuroendocrine tumor therapies are anticipated to enter the neuroendocrine tumors market in the forecast period and are expected to change the market. Some of the key emerging neuroendocrine tumor treatments include ITM-11 (N.C.A. 177LU-EDOTREOTIDE), CAM2029, RYZ101 (ACTINIUM-225 DOTATATE), CABOMETYX (Cabozantinib), ALPHAMEDIX (212PB-DOTAMTATE), [212PB] VMT- -NET , ELC-100 (ADVINCE), ONC201 , EO2401 + NIVOLUMAB , TIRAPAZAMINE (TEC-001) , and others. As the field of radioligand therapy evolves, there is an exciting shift towards alpha-emitting radioisotopes. At present, only beta-emitting radioisotopes are currently approved, companies are now focusing on developing alpha-emitters. In August 2024, Exelixis announced that its supplemental New Drug Application (sNDA) for CABOMETYX has been accepted in the US for: 1) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumors (pNET), and 2) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated extra-pancreatic NET (epNET). The US Food and Drug Administration (FDA) assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. In July 2024 , Curium announced that it had submitted its 505(b)(2) NDA for Lutetium Lu 177 Dotatate Injection for the treatment of somatostatin receptor-positive (SSTR+) GEP-NETS. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. Discover which therapies are expected to grab the NETs market share @ Neuroendocrine Tumors Market Report Neuroendocrine Tumors Overview Neuroendocrine Tumors (NETs) are a diverse group of cancers that arise from neuroendocrine cells, which have characteristics of both nerve cells and hormone-producing cells. These tumors can develop anywhere in the body but are most commonly found in the gastrointestinal tract, pancreas, and lungs. The exact causes of neuroendocrine tumors are not fully understood, but certain factors may increase risk, including genetic syndromes like multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau disease, and neurofibromatosis. Other potential contributors include chronic inflammatory conditions, smoking, and exposure to certain chemicals. Symptoms of NETs can vary widely depending on the tumor's location and whether it secretes hormones. Some tumors may be asymptomatic for a long time. Common symptoms include abdominal pain, diarrhea, flushing of the skin, unexplained weight loss, and in cases of hormone-secreting tumors, symptoms related to excess hormones, such as changes in blood sugar levels or high blood pressure. Diagnosing NETs typically involves a combination of blood and urine tests to detect hormone levels, imaging studies like CT, MRI, or PET scans, and biopsies to analyze tumor tissue. Specialized tests like chromogranin A (CgA) blood tests or somatostatin receptor scintigraphy (Octreoscan) may also be used to identify neuroendocrine activity and locate tumors. Neuroendocrine Tumors Epidemiology Segmentation The neuroendocrine tumors epidemiology section provides insights into the historical and current neuroendocrine tumors patient pool and forecasted trends for the 6MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The neuroendocrine tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 6MM segmented into: Total Incident Cases of NET Cases of NETs by Grade Stage-specific Cases of NET Cases of NETs by Site Cases of NETs by Functional Status Download the report to understand which factors are driving NETs epidemiology trends @ Neuroendocrine Tumors Epidemiological Insights Neuroendocrine Tumors Treatment Market Surgery is generally considered a first-line treatment for localized NETs. The frontline treatment for metastatic disease is somatostatin analogs, and currently, two agents are FDA-approved: SANDOSTATIN (octreotide acetate) and SOMATULINE DEPOT (lanreotide). Both somatostatin analogs provide symptomatic relief in 50% to 70% of patients and biochemical responses in 40% to 60% of patients. Traditionally, mTOR inhibitor – everolimus or sunitinib – was acknowledged as a second-line agent, but with the recent approval of PRRT (peptide receptor radionuclide therapy), the choice of second-line therapy is debatable. While GEP-NETs in children and adolescents are rare, the impact can be devastating. Advanced Accelerator Applications (AAA)/Novartis's LUTATHERA is now the very first therapy approved specifically for use in pediatric patients with GEP-NETs. offering new hope to young patients living with this rare cancer. In January 2018, the FDA approved LUTATHERA, a radiolabeled somatostatin analog for the treatment of GEP-NETs. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. LUTATHERA is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs. All available therapies for NETs, whether monotherapy or combination, are currently leveraged to treat this complex, diverse population of patients, yet no treatment has maintained progression-free survival (PFS) indefinitely. At present, the NETs market is dominated by SSAs, however, by 2034, radioligand therapies are projected to capture the highest market share, reflecting a paradigm shift driven by their enhanced efficacy and the growing adoption of targeted treatment approaches. While LUTATHERA has primarily been used as a second-line treatment, there is a growing interest in expanding its use to first-line settings for medium- and high-risk NETs. This trend underscores the rising prominence of radioligand therapies in redefining treatment standards in the NETs space. Learn more about the market of NETs @ Neuroendocrine Tumors Treatment Neuroendocrine Tumors Emerging Drugs and Companies Some of the drugs in the pipeline include ITM-11 (ITM Isotope Technologies Munich), CABOMETYX (Exelixis/Ipsen/Takeda), CAM2029 (Camurus), AlphaMedix (Radiomedix/Orano Med), VMT- -NET (Perspective Therapeutics), and others. CABOMETYX (cabozantinib) is a small-molecule inhibitor targeting several receptor tyrosine kinases, such as VEGFRs, MET, RET, and the TAM family (TYRO3, MER, AXL). In August 2024, the FDA accepted a supplemental New Drug Application (sNDA) for cabozantinib to treat patients with advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET) who have previously undergone treatment. The FDA set a PDUFA target date of April 3, 2025, for review and granted orphan drug designation for pNET. This application is supported by data from the Phase III CABINET trial, which studied CABOMETYX in these patient populations. ITM-11 (177Lu-edotreotide) , developed by ITM Isotope Technologies Munich , is a novel Targeted Radionuclide Therapy that combines two components: Edotreotide (DOTATOC), an octreotide-based somatostatin analog, and EndolucinBeta (n.c.a. lutetium-177 chloride), a low-energy beta-emitting synthetic radioisotope. It is currently under investigation in two Phase III clinical trials: COMPETE (NCT03049189) and COMPOSE (NCT04919226). COMPETE focuses on assessing ITM-11 for treating Grade 1 and Grade 2 GEP-NETs, while COMPOSE investigates its use in patients with well-differentiated high Grade 2 and Grade 3 GEP-NETs. ITM-11 was granted orphan designation for GEP-NET treatment based on Phase II data showing significant improvement in PFS. The other pipeline therapies for neuroendocrine tumors include RYZ101 (ACTINIUM-225 DOTATATE): BRISTOL MYERS SQUIBB/RAYZEBIO CAM2029: Camurus ALPHAMEDIX (212PB-DOTAMTATE): RADIOMEDIX/ORANO MED [212PB] VMT-α-NET: PERSPECTIVE THERAPEUTICS ELC-100 (ADVINCE): ELICERA THERAPEUTICS ONC201: CHIMERIX EO2401 + NIVOLUMAB: ENTEROME TIRAPAZAMINE (TEC-001): TECLISON It is more important than ever to ensure and understand supply chain and manufacturing issues of radiopharmaceuticals to stay at the forefront of radiopharmaceutical innovation, especially since a number of companies are investigating radiopharmaceuticals. Emerging key players should make sure that their product, supply, and production capabilities are adequate, and they should be prepared to meet the challenge of offering new therapeutic approaches to cancer patients who otherwise have limited options. In June 2024, BMS-RayzeBio was forced to pause a phase III trial due to an actinium shortage. Oncolytic virotherapy holds promise for cancer treatment. Oncolytic virotherapies like ELC100 (Elicera Therapeutics) and SVV-001 (Seneca therapeutics) are also being investigated for the treatment of NETs in early clinical trials. The anticipated launch of these emerging therapies are poised to transform the neuroendocrine tumors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the neuroendocrine tumors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about NETs clinical trials, visit @ Neuroendocrine Tumors Treatment Drugs Neuroendocrine Tumors Market Dynamics The neuroendocrine tumors market dynamics are anticipated to change in the coming years. NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes, and with advancements like LUTATHERA being the first therapy specifically approved for pediatric patients with GEP-NETs, along with continued research in targeted therapies such as somatostatin analogs and molecular inhibitors, there are growing opportunities for more effective and personalized treatments ; participation in clinical trials can further drive the discovery of new treatment modalities and improve patient outcomes. Furthermore, many potential therapies are being investigated for the treatment of NETs, and it is safe to predict that the treatment space will significantly impact the NETs market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the NETs market in the 6MM. However, several factors may impede the growth of the neuroendocrine tumors market. Since most of the NET cases comprise GEP-NETs, the lack of awareness among healthcare professionals and the general public often leads to delayed diagnosis and treatment . GEP-NETs are a heterogeneous group of tumors with diverse clinical presentations, making it difficult to develop standardized treatment protocols. Additionally, challenges in research and development , such as limited funding and resources, hinder advancements in the field, while the complexity of diagnosing GEP-NETs increases the risk of misdiagnosis or delayed diagnosis, resulting in suboptimal treatment outcomes. Moreover, neuroendocrine tumor treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the NETs market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . Neuroendocrine Tumors Report Metrics Details Study Period 2020–2034 Neuroendocrine Tumors Report Coverage 6MM [The United States, the EU-4 (Germany, France, Italy, and Spain), and the United Kingdom] Neuroendocrine Tumors Market Size in the US in 2023 USD 1.5 Billion Key Neuroendocrine Tumors Companies Novartis, Merck, Pfizer, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, Radiomedix, Orano Med, Perspective Therapeutics, Elicera Therapeutics, Chimerix, Enterome, Teclison, and others Key Neuroendocrine Tumors Therapies WELIREG, LUTATHERA, SOMATULINE DEPOT, AFINITOR, SUTENT, SANDOSTATIN LAR DEPOT, SANDOSTATIN, ITM-11 (N.C.A. 177LU-EDOTREOTIDE), CAM2029, RYZ101 (ACTINIUM-225 DOTATATE), CABOMETYX (CABOZANTINIB), ALPHAMEDIX (212PB-DOTAMTATE), [212PB] VMT--NET, ELC-100 (ADVINCE), ONC201, EO2401 + NIVOLUMAB, TIRAPAZAMINE (TEC-001), and others Scope of the Neuroendocrine Tumors Market Report Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and emerging therapies Neuroendocrine Tumors Market Dynamics: Conjoint Analysis of Emerging Neuroendocrine Tumors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Neuroendocrine Tumors Market Access and Reimbursement Discover more about neuroendocrine tumor drugs in development @ Neuroendocrine Tumors Clinical Trials Table of Contents 1 KEY INSIGHTS 2 REPORT INTRODUCTION 3 EXECUTIVE SUMMARY 4 NETS MARKET OVERVIEW AT A GLANCE 4.1 MARKET SHARE DISTRIBUTION (%) BY THERAPIES IN 2020 IN THE US 4.2 MARKET SHARE DISTRIBUTION (%) BY THERAPIES IN 2034 IN THE US 4.3 MARKET SHARE DISTRIBUTION (%) BY LINES OF THERAPIES IN 2020 IN THE US 4.4 MARKET SHARE DISTRIBUTION (%) BY LINES OF THERAPIES IN 2034 IN THE US 5 KEY EVENTS 6 EPIDEMIOLOGY AND MARKET METHODOLOGY 7 DISEASE BACKGROUND AND OVERVIEW 7.1 INTRODUCTION 7.2 SIGNS AND SYMPTOMS 7.3 CLASSIFICATION 7.4 RISK FACTORS 7.5 DIAGNOSIS 7.6 DIAGNOSTIC BIOMARKERS 7.7 DIFFERENTIAL DIAGNOSIS 7.8 STAGING 8 TREATMENT OF NETS 8.1 TREATMENT ALGORITHM 8.2 TREATMENT GUIDELINES 8.2.1 National Comprehensive Cancer Network (NCCN) Guidelines, 2024 8.2.1.1 NCCN Guidelines Version 2.2024 Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract (Well-Differentiated Grade 1/2), Lung, and Thymus 8.2.1.2 NCCN Guidelines Version 2.2024 Well-Differentiated, Grade 3 NETs 8.2.1.3 NCCN Guidelines Version 2.2024 NETs of the Pancreas (Well-differentiated Grade 1/2) 8.2.2 European Neuroendocrine Tumor Society (ENETS) 2023 Guidance Paper for Gastroduodenal NETs G1–G3 8.2.3 European Society for Medical Oncology, 2020 9 EPIDEMIOLOGY AND PATIENT POPULATION 9.1 KEY FINDINGS 9.2 ASSUMPTIONS AND RATIONALE 9.3 THE UNITED STATES 9.3.1 Total Incident Cases of NETs in the United States 9.3.2 Grade-specific Cases of NETs in the United States 9.3.3 Stage-specific Cases of NETs in the United States 9.3.4 Site-specific Cases of NETs in the United States 9.3.5 Cases of NETs by Functional Status in the United States 9.4 EU4 AND THE UK 9.4.1 Total Incident Cases of NETs in EU4 and the UK 9.4.2 Grade-specific Cases of NETs in EU4 and the UK 9.4.3 Stage-specific Cases of NETs in EU4 and the UK 9.4.4 Site-specific Cases of NETs in EU4 and the UK 9.4.5 Cases of NETs by Functional Status in EU4 and the UK 10 PATIENT JOURNEY 11 MARKETED DRUGS 11.1 KEY COMPETITORS 11.2 WELIREG (BELZUTIFAN/MK-6482): MERCK 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Developmental Activities 11.2.4 Current Pipeline Activity 11.2.4.1 Clinical Trials Information 11.2.5 Safety and Efficacy 11.3 LUTATHERA (LUTETIUM LU 177 DOTATATE): NOVARTIS 11.3.1 Product Description 11.3.2 Regulatory Milestones 11.3.3 Other Developmental Activities 11.3.4 Current Pipeline Activity 11.3.4.1 Clinical Trials Information 11.3.5 Safety and Efficacy 11.4 SUTENT (SUNITINIB MALATE): PFIZER 11.4.1 Product Description 11.4.2 Regulatory Milestone 11.4.3 Safety and Efficacy 11.5 AFINITOR (EVEROLIMUS): NOVARTIS 11.5.1 Product Description 11.5.2 Regulatory Milestones 11.5.3 Safety and Efficacy 11.6 SOMATULINE DEPOT (LANREOTIDE): IPSEN BIOPHARMACEUTICALS 11.6.1 Product Description 11.6.2 Regulatory Milestones 11.6.3 Other Developmental Activities 11.6.4 Safety and Efficacy 11.7 DEMSER (METYROSINE): BAUSCH HEALTH AND ONO PHARMACEUTICAL 11.7.1 Product Description 11.7.2 Regulatory Milestones 11.7.3 Other Developmental Activities 11.7.4 Safety and Efficacy 11.8 AZEDRA (IOBENGUANE I 131; RAIATT MIBG-I 131 INJECTION): PROGENICS PHARMACEUTICALS /LANTHEUS HOLDINGS AND FUJIFILM TOYAMA CHEMICAL 11.8.1 Product Description 11.8.2 Regulatory Milestones 11.8.3 Other Developmental Activities 11.8.4 Safety and Efficacy 12 EMERGING DRUGS 12.1 KEY COMPETITORS 12.2 ITM-11 (N.C.A. 177LU-EDOTREOTIDE): ITM SOLUCIN GMBH 12.2.1 Product Description 12.2.2 Other Developmental Activities 12.2.3 Clinical Development 12.2.3.1 Clinical Trial Information 12.2.4 Safety and Efficacy 12.3 CAM2029: CAMURUS 12.4 RYZ101 (ACTINIUM-225 DOTATATE): BRISTOL MYERS SQUIBB/RAYZEBIO 12.5 CABOMETYX (CABOZANTINIB): EXELIXIS/IPSEN/TAKEDA 12.6 ALPHAMEDIX (212PB-DOTAMTATE): RADIOMEDIX/ORANO MED 12.7 [212PB] VMT-Α-NET: PERSPECTIVE THERAPEUTICS 12.8 ELC-100 (ADVINCE): ELICERA THERAPEUTICS 12.9 ONC201: CHIMERIX 12.10. EO2401 + NIVOLUMAB: ENTEROME 12.11 TIRAPAZAMINE (TEC-001): TECLISON 13 NETS: MARKET ANALYSIS 13.1 KEY FINDINGS 13.2 MARKET OUTLOOK 13.3 CONJOINT ANALYSIS 13.1 KEY MARKET FORECAST ASSUMPTIONS 13.2 UNITED STATES MARKET SIZE 13.2.1 Total Market Size of NETs in the United States 13.2.2 Market Size of NETs by Therapies in the United States 13.3 EU4 AND THE UK MARKET SIZE 13.3.1 Total Market Size of NETs in EU4 and the UK 13.3.2 Market Size of NETs by Therapies in EU4 and the UK 14 NETs Market UNMET NEEDS 15 NETs Market SWOT ANALYSIS 16 NETs Market KOL VIEWS 17 MARKET ACCESS AND REIMBURSEMENT 17.1 UNITED STATES 17.1.1 Centre for Medicare and Medicaid Services (CMS) 17.2 EU4 AND THE UK 17.2.1 Germany 17.2.2 France 17.2.3 Italy 17.2.4 Spain 17.2.5 United Kingdom 17.3 MARKET ACCESS AND REIMBURSEMENT OF NETS 18 APPENDIX 18.1 BIBLIOGRAPHY 18.2 REPORT METHODOLOGY 19 DELVEINSIGHT CAPABILITIES 20 DISCLAIMER 21 ABOUT DELVEINSIGHT Related Reports Neuroendocrine Tumors Epidemiology Forecast Neuroendocrine Tumors Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted NETs epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. Neuroendocrine Tumors Pipeline Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NETs companies, including RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, among others. Gastroenteropancreatic Neuroendocrine Tumors Market Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, among others. Gastroenteropancreatic Neuroendocrine Tumors Pipeline Gastroenteropancreatic Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GEP-NET companies, including Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, among others. Pancreatic Neuroendocrine Tumors Market Pancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PNET companies including Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC, Ipsen, among others. Oncology Conference Coverage Services DelveInsight's Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies. Other Business Consulting Services Healthcare Competitive Intelligence Healthcare Licensing Services Healthcare Portfolio Management Case Study Learn how the engagement with respected KOLs bolstered the client's reputation as a leader in the pharma industry at KOL Profiling About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn | Facebook | Twitter © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.AP News Summary at 10:24 a.m. EST
SAN DIEGO (AP) — Mark Few liked what he saw unfold at San Diego State's Viejas Arena when his No. 3 Gonzaga Bulldogs made their first foray outside of Spokane, Washington, this season. A double-digit victory in a packed, loud arena. Toughness from a deep, experienced lineup that once again is driven to win an elusive national championship. And, peeking a few seasons ahead, he saw an SDSU team that he views more as a future Pac-12 partner than rival. Behind big man Graham Ike and guard Ryan Nembhard, Gonzaga displayed its size, speed and strength in beating Brian Dutcher's young, hobbled squad 80-67 on Monday night. The Bulldogs returned the favor after SDSU won 84-74 last December at The Kennel in Spokane, which ended their 59-game nonconference winning streak. Both teams reached the Sweet Sixteen last season. Gonzaga is the only team in the nation to reach the Sweet Sixteen the last nine seasons as the Bulldogs extended their streak of NCAA Tournament appearances to 25 straight. Back in Spokane on Wednesday night, the Zags improved to 5-0 by routing Long Beach State 84-41, no doubt firing up expectations in the Lilac City and beyond. In a college sports climate dominated by NIL and the transfer portal, the Zags are stacked. Of the 12 possible players who could return from last year, 10 did, including all four starters. They returned 81% of last season's scoring and 71% of their rebounding. Six of its top seven scorers are back, along with 81.4% of minutes played. “We're tougher,” Few said. “We're physically tougher, we're mentally tougher, at least so far in the season. A lot of the same guys from last year. That's what happens when you stick around a couple of years. “You've got to have both to be able to go on the road in a place like this and dig out wins," Few added. "That's one thing San Diego State is going to bring. They're going to bring physicality, they're going to bring great athleticism, they're going to challenge you in every facet of the game.” Hoops powerhouse Gonzaga announced on Oct. 1 that it will move from the West Coast Conference, where it has dominated for most of the last quarter-century, into a Pac-12 conference being rebuilt around football. Beginning with the 2026-27 academic year, Gonzaga will become the eighth member along with holdovers Washington State and Oregon State, and fellow newcomers Boise State, San Diego State, Fresno State, Utah State and Colorado State from the Mountain West. While not as dominant as the Zags, the Aztecs have been one of the West Coast's best programs for several years, first under Steve Fisher and then Dutcher, his longtime assistant who is in his eighth season as head coach. “They're just going to be such a great partner, because they value basketball and they support basketball,” said Few, who's in his 26th season as head coach. “They understand, when you have a national program like we both have, it pays unbelievable dividends to the university, to the community, to the city and the state, like the Northwest and down here. They get that. We're looking for other like-minded places to partner with us.” Few said he would often chat with Fisher about the possibility of the Zags and Aztecs playing in the same conference. Fisher watches Aztecs games with his wife, Angie, from the second row above Steve Fisher Court. “We talked about it forever,” Few said. “I'm happy for Dutch. He's doing a great job." San Diego State reached its first Final Four in 2023, when Lamont Butler's thrilling buzzer-beater against Florida Atlantic lifted the Aztecs into the national championship game, where they lost 76-59 to UConn. SDSU was routed again by UConn, 82-52, in last season's Sweet Sixteen, while Gonzaga lost to Purdue. Gonzaga opened this season with a 101-63 win against then-No. 8 Baylor at the Spokane Arena. It was Gonzaga’s biggest victory margin over a top-10 opponent, over a team it lost to in the 2021 national title game in Indianapolis. Nembhard, who had 19 points and 10 assists against the Aztecs, said the Zags “did a really good job, actually,” of handling the pressure of playing at Viejas Arena. "Every time they went on a little run and the crowd got loud, we did a good job staying composed and trusting our offensive sets.” Nembhard will be gone when the Bulldogs and Aztecs are in the Pac-12 together, but thinks "the rivalry will be great. This is a great program. I played them a couple of times at Creighton, and they always gave us a tough game. They have a great fan base, a great coach over there, and they play really hard. I think it’ll be a great rivalry to come.” ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball